Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are studying the effects of elritercept TAK-226, KER-050 in treating anemia in adults with very low, low, or intermediate-risk myelodysplastic syndromes MDS who require regular blood transfusions. This Phase 3, randomized, double-blind, placebo-controlled trial aims to find out how well elritercept reduces the need for red blood cell RBC transfusions, especially over longer periods or in adults with high transfusion needs. The study also monitors the safety and tolerability of elritercept. Participants who qualify will be randomly assigned in a 21 ratio to receive either elritercept or a matching placebo by subcutaneous injection every 4 weeks. The study includes a Primary Phase lasting 24 weeks, followed by a Secondary Phase of an additional 24 weeks, during which the same blinded treatment continues. Study visits are scheduled every 2 weeks for the first 6 cycles and every 4 weeks thereafter. An Extension Phase allows eligible participants to continue treatment until they choose to stop or the study is unblinded. Throughout the study, participants will undergo regular assessments including MDS disease evaluations every 24 weeks, laboratory tests, vital sign monitoring, and safety follow-up visits every 4 weeks for 8 weeks after the last dose. Long-term follow-up will continue quarterly for up to 5 years to monitor ongoing health status. The main outcome measured is the percentage of participants achieving transfusion independence for at least 8 weeks during the first 24 weeks of treatment.
Actively Recruiting
Researchers are conducting an 18-month Phase 3 clinical trial to study the safety and efficacy of oral nizubaglustat AZ-3102 in children and young people aged 4 years and older with late-infantile and juvenile forms of Niemann-Pick Type C NPC disease. This randomized, double-blind, placebo-controlled study aims to compare the effects of nizubaglustat against placebo on ataxic symptoms and other disease manifestations in this rare neurological condition. Participants will receive once-daily oral dispersible tablets of either nizubaglustat or a matching placebo over 18 months. The study examines the drugs pharmacokinetics and pharmacodynamics, along with its safety and tolerability. The trial is conducted at multiple centers and includes a parallel study design where participants are randomly assigned to one of the two groups. Throughout the study, participants will undergo regular assessments including the Scale for the Assessment and Rating of Ataxia SARA, Vineland Adaptive Behavior Scale, Penetration-Aspiration Scale, and several other evaluations at baseline and at months 6, 12, and 18. Researchers will also monitor seizure frequency and drug plasma levels, as well as record any adverse effects. The primary outcomes focus on changes in ataxia scores over the 18-month period to evaluate the treatments impact.
Actively Recruiting
Researchers are studying the safety and effects of oral nizubaglustat AZ-3102 in children aged 4 years and older with late-infantile or juvenile forms of Niemann-Pick type C disease, GM1 gangliosidosis, or GM2 gangliosidosis. This Phase 3 study is double-blinded, randomized, placebo-controlled, and conducted at multiple centers. It uses a Master Protocol Research Program with different subprotocols for each disease type to evaluate treatment outcomes. Participants are randomly assigned in a 21 ratio to receive either oral nizubaglustat or a matching placebo. The study lasts 18 months and includes separate subprotocols for Niemann-Pick type C disease and for GM1 or GM2 gangliosidosis. Each subprotocol may have additional eligibility criteria and specific safety and efficacy assessments. During the study, participants undergo evaluations defined in their disease-specific subprotocols. Researchers monitor safety and efficacy throughout the 18-month period, tracking the number of participants assigned to each subprotocol. The study aims to gather detailed information on the treatments impact over this timeframe, with continuous monitoring to assess participant health and responses.
Actively Recruiting
Researchers are conducting a Phase 1 study to evaluate the safety and tolerability of SBO-154 in adults with advanced solid tumors who have either not responded to or cannot tolerate standard treatments. The study aims to find the highest dose of SBO-154 that patients can safely tolerate and then further assess its safety in specific advanced cancers. The study is divided into two parts. In Part 1, participants receive escalating doses of SBO-154 administered intravenously every three weeks to determine the maximum tolerated dose. In Part 2, the safety of the selected doses from Part 1 is further evaluated in patients with particular types of advanced solid tumors. Treatment continues with dosing every three weeks during the study period. Participants will be closely monitored through scheduled visits involving laboratory tests and assessments to track any dose-limiting toxicities and treatment-related adverse events up to 30 days after the last dose. Researchers will also evaluate tumor response using imaging every six weeks for up to 12 months and monitor the presence of anti-drug antibodies for up to one year. The overall study duration extends through 2030, with ongoing safety and response evaluations.
Actively Recruiting
Researchers are evaluating how the study medicine dazukibart works in people with active idiopathic inflammatory myopathies, specifically dermatomyositis DM and polymyositis PM. These are conditions where muscles important for movement become inflamed, causing weakness in areas like hips, thighs, upper arms, and neck. DM can also cause a skin rash and these disorders may affect lung and heart function, impacting patients quality of life and daily functioning. Participants who previously took part in a study with dazukibart may enroll. Those receiving the medicine will get it through intravenous infusion every 4 weeks for about 12 months, totaling approximately 18 visits over 16 months. A safety follow-up period of about 4 months follows the last infusion. Some participants will not receive the study medicine but will take part in safety follow-up visits every 4 weeks, up to 4 visits. Throughout the study, participants will have regular assessments including monitoring for adverse events, laboratory tests, vital signs, electrocardiograms, lung function tests, and evaluations of muscle strength and disease activity. Patient-reported outcomes such as physical function, fatigue, and quality of life will also be collected. Safety follow-up continues after treatment ends, with total participation lasting about 16 months or up to 20 months for follow-up-only participants.